Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

MLA

Liu, Xinxue, et al. “Persistence of Immunogenicity after Seven COVID-19 Vaccines given as Third Dose Boosters Following Two Doses of ChAdOx1 NCov-19 or BNT162b2 in the UK: Three Month Analyses of the COV-BOOST Trial.” The Journal of Infection, vol. 84, no. 6, June 2022, pp. 795–813. EBSCOhost, https://doi.org/10.1016/j.jinf.2022.04.018.

APA

Liu, X., Munro, A. P. S., Feng, S., Janani, L., Aley, P. K., Babbage, G., Baxter, D., Bula, M., Cathie, K., Chatterjee, K., Dejnirattisai, W., Dodd, K., Enever, Y., Qureshi, E., Goodman, A. L., Green, C. A., Harndahl, L., Haughney, J., Hicks, A., … Faust, S. N. (2022). Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. The Journal of Infection, 84(6), 795–813. https://doi.org/10.1016/j.jinf.2022.04.018

Chicago

Liu, Xinxue, Alasdair P S Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Gavin Babbage, David Baxter, et al. 2022. “Persistence of Immunogenicity after Seven COVID-19 Vaccines given as Third Dose Boosters Following Two Doses of ChAdOx1 NCov-19 or BNT162b2 in the UK: Three Month Analyses of the COV-BOOST Trial.” The Journal of Infection 84 (6): 795–813. doi:10.1016/j.jinf.2022.04.018.